US FDA marks Lupin’s ‘sartans’ safe, but still issues one observation

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Gustavofrazao)
(Image: Getty/Gustavofrazao)

Related tags Lupin Pharmaceuticals India Fda

The US FDA’s inspection of Lupin gave its manufacturing process for its ‘sartan’ products the all clear but managed to find one “procedural deficiency”.

Lupin Pharmaceuticals, the third largest Indian pharma company, issued a regulatory filing announcing that it had been inspected by the US Food and Drug Administration (FDA) between August 27 and August 31, 2018.

The inspection looked into Lupin’s current good manufacturing practices (cGMP), but also had another focus; the agency examined Lupin’s ‘sartan’ active pharmaceuticals ingredients (APIs), including valsartan, losartan, and irbesartan.

The decision to observe the manufacturing procedure of the sartan products occurred as issues have been found in the production of valsartan among certain Chinese companies​.

The FDA did not find any issues at Lupin’s facility in Tarapur, Indian. The company stated in a release​: “the US FDA concluded that the manufacturing processes of Lupin ‘sartans’ are safe with no chance of presence of the NDMA [N-Nitrosodimethylamine] impurity in the APIs.”

The occurrence of NDMA in a number of valsartan medications has led to numerous FDA notices regarding voluntary recalls​ by companies for products with contaminated APIs. NDMA is classified as a probable carcinogen by the WHO​.

Despite not finding any issues in the production of the sartans, the FDA did observe a procedural deficiency at the Tarapur site, which encompasses 14 manufacturing plants and five solvent recovery blocks.

Lupin did not reveal in its release what the observed procedural deficiency was in regards to nor the timeframe for rectifying the issue.

It’s not the first time that Lupin has faced issues with its India-based facilities. Lupin’s sites in Goa and Indore received warning letters at the end of last year due to GMP issues​.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars